Update on the Divestment of a Womens Health Product in Europe to Ennogen
TransactionMaterial
In brief
The divestment of commercialisation rights and related intellectual property for Ovestin in Europe to Ennogen Healthcare International Limited has completed. Aspen received the purchase consideration of EUR 197 million on 3 November 2026.
The announcement
Update on the Divestment of a Women’s Health Product in Europe to Ennogen ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number: 1985/002935/06 Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries (collectively “Aspen” or “the Group”) UPDATE ON THE DIVESTMENT OF A WOMEN’S HEALTH PRODUCT IN EUROPE TO ENNOGEN Shareholders are referred to the announcement released on SENS on 2 November 2026 relating to the divestment by Aspen’s wholly owned subsidiary, Aspen Global Incorporated, of the commercialisation rights and related intellectual property relating to Ovestin in Europe (the “Assets”) to Ennogen Healthcare International Limited (“Ennogen”) for a purchase consideration of EUR 197 million, plus the cost of the related inventory (the “Transaction”). As stated in that announcement, completion of the Transaction was subject to the condition precedent that Ennogen’s funding arrangements become unconditional, with the purchase consideration of EUR 197 million for the Assets payable on completion. Aspen is pleased to confirm that the condition precedent has been satisfied, the purchase consideration of EUR 197 million for the Assets was received by Aspen on 3 November 2026 and, accordingly, the Transaction has been completed. Durban 5 November 2026 Sponsor Investec Bank Limited Date: 05/11/2026 07:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.